StockNews.com Initiates Coverage on Aptose Biosciences (NASDAQ:APTO)

StockNews.com started coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report released on Wednesday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Aptose Biosciences Stock Performance

Aptose Biosciences stock opened at $0.36 on Wednesday. The company has a 50 day moving average price of $0.38 and a 200 day moving average price of $0.64. Aptose Biosciences has a 52 week low of $0.33 and a 52 week high of $2.91. The firm has a market capitalization of $6.61 million, a price-to-earnings ratio of -0.12 and a beta of 1.26.

Institutional Investors Weigh In On Aptose Biosciences

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp raised its stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 401,750 shares of the biotechnology company’s stock after buying an additional 167,282 shares during the period. Sigma Planning Corp owned about 2.22% of Aptose Biosciences worth $165,000 as of its most recent SEC filing. 26.62% of the stock is currently owned by institutional investors.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.